Aleafia Health Inc. ALEAF AH Q2 2023 net revenue was CA$10.6 million ($7.9 million), a 10.4% increase compared to CA$9.6 million in the prior year.
Q2 2023 Financial Highlights
-
Adjusted EBITDA was CA$83,000, compared to a loss of CA$8.9 million in Q2 2022.
-
Gross profit was CA$15.6 million compared to a loss of CA$490,000 in Q2 2022.
-
Net profit and comprehensive profit was CA$7 million, compared to a loss of CA$80.3 million in Q2 2022.
“We have worked diligently over the past 12 months to achieve this major milestone, and to be among the first publicly traded Canadian Licensed Producers to reach adjusted EBITDA profitability is an enormous accomplishment,” stated Tricia Symmes, CEO.
“It is the result of a relentlessly profit-focused management team putting into place the discipline and high-growth mindset instrumental in achieving this meaningful and substantial objective. The fact that this occurred during a period of market volatility with the OCS cybersecurity attack, the BC lockout and our whole flower supply constraints all impacting adult-use sales, is an even stronger testament to the power of our growing brands, led by Divvy,” continued Symmes.
Cost Savings
In Q3 FY2023, the company is enacting further cost savings initiatives with the wind down of its Grimsby greenhouse, representing an annualized net savings of approximately CA$4.1 million. The company will commence the process of winding down operations, effective November 2022, impacting 41 employees.
Price Action
Aleafia Health shares were trading 8.67% higher at $0.0619 per share at the time of writing Wednesday morning.
Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.
Photo by Esteban Lopez on Unsplash
Related News
Aleafia Health Q1 2023 Revenue Grows 41% YoY, What About Profit?
Aleafia Health Reaffirms Revenue Guidance, Implements $6.7 Million In Annualized Cost Savings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.